pyrrolopyridine - Ontology Report

DDR1-IN-2 inhibits the reaction [collagen increases DDR1 autophosphorylation in human cell lines]

RGD

PMID:23899692

RGD:152995467

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

pexidartinib

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Csf1

colony stimulating factor 1

decreases secretion

pexidartinib results in decreased secretion of CSF1 protein

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

Csf1r

colony stimulating factor 1 receptor

decreases activity

pexidartinib results in decreased activity of CSF1R protein

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

Flt3

Fms related receptor tyrosine kinase 3

decreases activity

pexidartinib results in decreased activity of FLT3 protein

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

Kit

KIT proto-oncogene receptor tyrosine kinase

decreases activity

pexidartinib results in decreased activity of KIT protein

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

PLX-4720

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Hsf1

heat shock transcription factor 1

decreases activity

PLX 4720 results in decreased activity of HSF1 protein

PMID:34170685

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

vemurafenib

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Acaca

acetyl-CoA carboxylase alpha

multiple interactions

[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

Acly

ATP citrate lyase

multiple interactions

[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

Akt1

AKT serine/threonine kinase 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

Apaf1

apoptotic peptidase activating factor 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

Bad

BCL2-associated agonist of cell death

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

Bax

BCL2 associated X, apoptosis regulator

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bbc3

Bcl-2 binding component 3

multiple interactions

[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

Bcl2

BCL2, apoptosis regulator

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Bcl2l1

Bcl2-like 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

Bcl2l11

Bcl2-like 11

multiple interactions

[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

Birc5

baculoviral IAP repeat-containing 5

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Braf

B-Raf proto-oncogene, serine/threonine kinase

decreases activity
affects response to substance
increases response to substance
multiple interactions

Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form
BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib
BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA]

PMID:20823850 PMID:21185263 PMID:23237741 PMID:24859340 PMID:26640592 More...

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

Casp3

caspase 3

multiple interactions

[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp8

caspase 8

multiple interactions

[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

Ccl2

C-C motif chemokine ligand 2

increases secretion
increases expression
decreases response to substance

vemurafenib results in increased secretion of CCL2 protein
vemurafenib results in increased expression of CCL2 mRNA
CCL2 protein results in decreased susceptibility to vemurafenib

PMID:26684239

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

Ccnb1

cyclin B1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

Ccnd1

cyclin D1

multiple interactions
decreases expression

CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]
vemurafenib results in decreased expression of CCND1 protein

PMID:26978007 PMID:27087167

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

Ccne1

cyclin E1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

Cd40

CD40 molecule

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40 protein

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

Cd40lg

CD40 ligand

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40LG protein

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

Cd70

Cd70 molecule

decreases expression
multiple interactions

vemurafenib results in decreased expression of CD70 protein
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]

PMID:26828592

NCBI chr 9:2,006,563...2,009,715
Ensembl chr 9:2,006,563...2,009,715

Cdc25a

cell division cycle 25A

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

Cdc25c

cell division cycle 25C

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

Cdk4

cyclin-dependent kinase 4

decreases expression

vemurafenib results in decreased expression of CDK4 protein

PMID:27087167

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

Cdkn1b

cyclin-dependent kinase inhibitor 1B

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

Chek1

checkpoint kinase 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CHEK1 mRNA

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

Ddit3

DNA-damage inducible transcript 3

multiple interactions

[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

Dio3

iodothyronine deiodinase 3

decreases expression

vemurafenib results in decreased expression of DIO3

PMID:26825960

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

E2f1

E2F transcription factor 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

Ehf

ets homologous factor

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of EHF mRNA

NCBI chr 3:89,639,845...89,680,061
Ensembl chr 3:89,641,833...89,679,997

Elk1

ETS transcription factor ELK1

multiple interactions

[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

Ern1

endoplasmic reticulum to nucleus signaling 1

multiple interactions

[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

Ezh2

enhancer of zeste 2 polycomb repressive complex 2 subunit

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of EZH2 mRNA

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

Faslg

Fas ligand

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

Fasn

fatty acid synthase

multiple interactions

[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

Hgf

hepatocyte growth factor

multiple interactions

[MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

Hif1a

hypoxia inducible factor 1 subunit alpha

increases expression

vemurafenib results in increased expression of HIF1A mRNA

PMID:26684239

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

Hspa1a

heat shock protein family A (Hsp70) member 1A

decreases response to substance

HSPA1A protein results in decreased susceptibility to vemurafenib

PMID:26984758

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

Hspa5

heat shock protein family A (Hsp70) member 5

multiple interactions

[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

Htra1

HtrA serine peptidase 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of HTRA1 protein

NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379

Igfbp1

insulin-like growth factor binding protein 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP1 protein

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

Igfbp2

insulin-like growth factor binding protein 2

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP2 protein

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

Igfbp6

insulin-like growth factor binding protein 6

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP6 protein

NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966

Kras

KRAS proto-oncogene, GTPase

affects response to substance
multiple interactions

KRAS protein mutant form affects the susceptibility to vemurafenib
[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]; Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]

NCBI chr 4:178,185,418...178,218,484

Map1lc3a

microtubule-associated protein 1 light chain 3 alpha

multiple interactions

[Vemurafenib co-treated with 3,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-one] affects the localization of MAP1LC3A protein

PMID:35648318

NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670

Mapk1

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation

[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]
vemurafenib results in increased phosphorylation of MAPK1 protein
vemurafenib results in decreased phosphorylation of MAPK1 protein

PMID:26640592 PMID:26668268 PMID:26751190 PMID:26828592 PMID:26978007 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

Mapk3

mitogen activated protein kinase 3

decreases phosphorylation
increases phosphorylation
multiple interactions

vemurafenib results in decreased phosphorylation of MAPK3 protein
vemurafenib results in increased phosphorylation of MAPK3 protein
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]

PMID:26640592 PMID:26668268 PMID:26751190 PMID:26828592 PMID:26978007 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

Mcl1

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MCL1 mRNA

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

Met

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

Mitf

melanocyte inducing transcription factor

affects expression

vemurafenib affects the expression of MITF protein

NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145

Mki67

marker of proliferation Ki-67

multiple interactions

[Vemurafenib co-treated with 3,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-one] results in decreased expression of MKI67 protein

PMID:35648318

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

Mlana

melan-A

increases expression

vemurafenib results in increased expression of MLANA mRNA; vemurafenib results in increased expression of MLANA protein

NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343

Mmp1

matrix metallopeptidase 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

Myc

MYC proto-oncogene, bHLH transcription factor

decreases expression
multiple interactions

vemurafenib results in decreased expression of MYC protein
(+)-JQ1 compound promotes the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; vemurafenib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]

PMID:26284497 PMID:26668268

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

Nras

NRAS proto-oncogene, GTPase

affects response to substance
multiple interactions

NRAS protein mutant form affects the susceptibility to vemurafenib
[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein

NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions

[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [Vemurafenib co-treated with 3,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-one] results in increased cleavage of PARP1 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]

PMID:27222248 PMID:35648318

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pmel

premelanosome protein

increases expression

vemurafenib results in increased expression of PMEL mRNA; vemurafenib results in increased expression of PMEL protein

NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746

Ptgs2

prostaglandin-endoperoxide synthase 2

decreases expression

vemurafenib results in decreased expression of PTGS2 protein

PMID:27087167

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

Raf1

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

Slc5a5

solute carrier family 5 member 5

multiple interactions

[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA; [vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]]; TSHB protein promotes the reaction [[vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]

NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697

Srebf1

sterol regulatory element binding transcription factor 1

decreases cleavage
multiple interactions
decreases expression

Vemurafenib results in decreased cleavage of SREBF1 protein
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]
Vemurafenib results in decreased expression of SREBF1 mRNA alternative form

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

thyroglobulin

multiple interactions

[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]

NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210

Tgfa

transforming growth factor alpha

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

Tgfb1

transforming growth factor, beta 1

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

Tnf

tumor necrosis factor

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Tnfrsf10b

TNF receptor superfamily member 10b

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF10A protein

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

Tnfrsf1b

TNF receptor superfamily member 1B

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF1B protein

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

Tnfrsf21

TNF receptor superfamily member 21

multiple interactions

[(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF21 protein

NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085

Tnfrsf22

tumor necrosis factor receptor superfamily, member 22

multiple interactions

[(+)-JQ1 compound co-treated with Vemurafenib] results in increased expression of TNFRSF10C protein

NCBI chr 1:198,840,452...198,860,713
Ensembl chr 1:198,840,453...198,856,309

Tpo

thyroid peroxidase

multiple interactions

[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]

NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199

Tshb

thyroid stimulating hormone subunit beta

multiple interactions

[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

Tshr

thyroid stimulating hormone receptor

multiple interactions

[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]

NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538

Tyr

tyrosinase

increases expression

Vemurafenib results in increased expression of TYR mRNA; Vemurafenib results in increased expression of TYR protein

NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207

Tyrp1

tyrosinase-related protein 1

increases expression

vemurafenib results in increased expression of TYRP1 protein

NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516

Wwtr1

WW domain containing transcription regulator 1

affects localization

vemurafenib affects the localization of WWTR1 protein

PMID:26668268

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968

Yap1

Yes1 associated transcriptional regulator

multiple interactions
affects localization
decreases response to substance

[YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK1 protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK3 protein]
vemurafenib affects the localization of YAP1 protein

PMID:26668268

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

venetoclax

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

Abcb1a

ATP binding cassette subfamily B member 1A

multiple interactions

[venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]

PMID:34963561

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

Abcg2

ATP binding cassette subfamily G member 2

affects binding

venetoclax binds to ABCG2 protein

PMID:33954893

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

Bak1

BCL2-antagonist/killer 1

affects folding

venetoclax affects the folding of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

Bax

BCL2 associated X, apoptosis regulator

affects folding

venetoclax affects the folding of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bbc3

Bcl-2 binding component 3

affects response to substance
multiple interactions

BBC3 protein affects the susceptibility to venetoclax
2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [BBC3 protein affects the susceptibility to venetoclax]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]

PMID:37956312

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

Bcl2

BCL2, apoptosis regulator

decreases activity
decreases expression
multiple interactions

venetoclax results in decreased activity of BCL2 protein
venetoclax results in decreased expression of BCL2 protein
[9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of BCL2 protein; [mivebresib co-treated with venetoclax] results in decreased expression of BCL2 protein

PMID:26214592 PMID:30647404 PMID:37754227

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Bcl2l1

Bcl2-like 1

decreases expression
multiple interactions

venetoclax results in decreased expression of BCL2L1 protein
[mivebresib co-treated with venetoclax] results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

Birc5

baculoviral IAP repeat-containing 5

multiple interactions

[sepantronium co-treated with venetoclax] results in decreased expression of BIRC5 protein

PMID:31837377

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Btrc

beta-transducin repeat containing E3 ubiquitin protein ligase

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]

NCBI chr 1:244,210,299...244,380,126
Ensembl chr 1:244,210,314...244,376,721

Casp3

caspase 3

multiple interactions
increases cleavage

[venetoclax co-treated with sepantronium] results in increased cleavage of CASP3 protein; venetoclax inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of CASP3 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of CASP3 protein]

PMID:31837377 PMID:34303041 PMID:34861246

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp9

caspase 9

multiple interactions

[venetoclax co-treated with sepantronium] results in increased cleavage of CASP9 protein

PMID:31837377

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

Ccl2

C-C motif chemokine ligand 2

multiple interactions

Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCP1 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

Cdk6

cyclin-dependent kinase 6

multiple interactions

[mivebresib co-treated with venetoclax] results in decreased expression of CDK6 protein

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

Flt3

Fms related receptor tyrosine kinase 3

decreases expression
multiple interactions

venetoclax results in decreased expression of FLT3 protein
9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- promotes the reaction [venetoclax results in decreased expression of FLT3 protein]; [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of FLT3 protein

PMID:37754227

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

Mapk1

mitogen activated protein kinase 1

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK1 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

Mapk3

mitogen activated protein kinase 3

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK3 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

Mcl1

MCL1 apoptosis regulator, BCL2 family member

increases expression
decreases expression
multiple interactions

venetoclax results in increased expression of MCL1 protein
venetoclax results in decreased expression of MCL1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; [mivebresib co-treated with venetoclax] results in decreased expression of MCL1 protein; [sepantronium co-treated with venetoclax] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]

PMID:30647404 PMID:31837377 PMID:35561756 PMID:37754227

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

Myc

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[mivebresib co-treated with venetoclax] results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

Nox4

NADPH oxidase 4

multiple interactions

[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 protein; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 protein

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

[mivebresib co-treated with venetoclax] results in increased cleavage of PARP1 protein; [venetoclax co-treated with sepantronium] results in increased cleavage of PARP1 protein; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of PARP1 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of PARP1 protein]

PMID:30647404 PMID:31837377 PMID:34861246

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pmaip1

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions
affects response to substance
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]
PMAIP1 protein affects the susceptibility to venetoclax
venetoclax results in increased expression of PMAIP1 protein

PMID:30647404 PMID:35561756 PMID:37956312

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

Sp1

Sp1 transcription factor

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of and results in increased stability of SP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

Sqstm1

sequestosome 1

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein; [venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]